Item 8.01. Other Events.

As previously reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission by INmune Bio Inc., a Nevada corporation (the "Company"), on March 16, 2021 (the "8-K"), on March 15, 2021, David, J. Moss, Chief Financial Officer of the Company entered into a 10b5-1 trading plan in accordance with Rule 10b5-1 of the Securities Exchange act of 1934, as amended (the "Moss Plan") for trading 275,000 shares of the Company's common stock owned by Mr. Moss. On January 26, 2022, Mr. Moss terminated the Moss Plan. As of the termination of the Moss Plan, 29,259 shares of the Company's common stock were sold pursuant to the Moss Plan.

As previously reported in the 8-K, on March 15, 2021, Raymond J. Tesi, Chief Executive Officer and a member of the Board of Directors the Company, entered into a 10b5-1 trading plan in accordance with Rule 10b5-1 of the Securities Exchange act of 1934, as amended (the "Tesi Plan") for trading 120,000 shares of the Company's common stock owned by Dr. Tesi. On, January 24, 2022, Dr. Tesi terminated the Tesi Plan. As of the termination of the Tesi Plan, 63,759 shares of the Company's common stock were sold pursuant to the Tesi Plan.

As previously reported in the 8-K, on March 15, 2021, Mark Lowdell, Chief Scientific Officer of the Company, entered into a 10b5-1 trading plan in accordance with Rule 10b5-1 of the Securities Exchange act of 1934, as amended (the "Lowdell Plan") for trading 120,000 shares of the Company's common stock owned by Dr. Lowdell. On January 25, 2022, Dr. Lowdell terminated the Lowdell Plan. As of the termination of the Lowdell Plan, 33,458 shares of the Company's common stock were sold pursuant to the Lowdell Plan.







                                       1

© Edgar Online, source Glimpses